Enterprise Value
3.771B
Cash
267.1M
Avg Qtr Burn
-31.58M
Short % of Float
7.52%
Insider Ownership
0.86%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Galafold (migalastat) Details Fabry disease | Approved Quarterly sales | |
AT-GAA (cipaglucosidase alfa co-administered with miglustat) Details Pompe Disease Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
AT-GTX-501 Details Batten Disease | Failed Discontinued | |
AT-GTX-502 Details Batten Disease | Failed Discontinued |